Johanna Friedl-Naderer Sells Shares of Dyne Therapeutics, Inc. $DYN

Editorial illustration for Dyne Therapeutics, Inc. (DYN)

Key Points

  • Johanna Friedl-Naderer sold 145 shares of Dyne Therapeutics, Inc. ($DYN) worth $2,657.85.
  • $DYN last traded around $19.20.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Johanna Friedl-Naderer, Chief Commercial Officer at Dyne Therapeutics, Inc. ($DYN), sold 145 shares at an average price of $18.33, for a total transaction of $2,657.85. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics, Inc. Stock Down 23.4%

Shares of Dyne Therapeutics, Inc. ($DYN) traded around $19.20 on Wednesday, down 23.4% for the day.

Last price$19.20
Market cap$4.75B
Forward P/E-7.61
Beta1.08
52-week low$11.92
52-week high$27.30
50-day MA$24.30
200-day MA$19.77
Current ratio12.02
Quick ratio11.52
Debt-to-equity0.33

Dyne Therapeutics, Inc. Earnings

EPS (ttm)-$3.26
Revenue (ttm)
Net margin0%
Return on equity-81.57%
Next earningsNov 5, 2026

Analysts Set New Price Targets

ConsensusStrong Buy
Average target$39.40
High target$50
Low target$17
Analysts covering15

About Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

ExchangeNasdaqGS
SectorHealthcare
IndustryBiotechnology
HeadquartersWaltham, MA
CEOMr. John G. Cox M.B.A.
Employees289

Get Dyne Therapeutics, Inc. alerts

New 13F filings, insider trades, and analyst moves on $DYN, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.